According to GSK, AREXVY RSV vaccine efficacy was reported to be 82.6 percent against the first occurrence of RSV related lower respiratory tract infection in persons 60 through 79 years of age. Data was not sufficient to determine the efficacy of the vaccine in persons 80 years of age and older. Vaccine efficacy in persons with immunocompromising conditions is also unknown.
Based on available data presented during the February 2023 ACIP meeting, vaccine efficacy for the GSK vaccine peaked at two months post-vaccination and by one year, offered no vaccine acquired protection. Additional data provided by the manufacturer during the June 2023 ACIP meeting showed that giving another dose of the vaccine one year later had no impact on boosting the immune response.
